Management of Acute Myeloid Leukemia: A Review
Targeted therapies have improved outcomes in molecularly defined subsets of AML, with menin, <i>IDH</i> and <i>FLT3</i> inhibitors representing major advances. However, <i>TP53</i>-mutated AML continues to carry a dismal prognosis, underscoring the need for more effective therapeutic strategies. Continued biomarker-driven research, novel drug combinations, and mechanistic insights will be essential to further refine AML treatment and improve long-term survival across disease subsets.
Authors
- Gina Keiffer
- Chetan Jeurkar (ORCID: https://orcid.org/0000-0001-6127-2251)
- Lindsay Wilde (ORCID: https://orcid.org/0000-0002-7482-7970)
- Margaret Kasner (ORCID: https://orcid.org/0000-0001-8616-744X)
- David Sung Hyeon Baek
- Lana King
Institutions
- Thomas Jefferson University (US)
- Sidney Kimmel Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3390/cancers18040659
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00